Former Orbital scientists launch ParcelBio with $13 million seed round to boost mRNA therapy durability
read at Endpoints ↗DealPositive
Two former Orbital Therapeutics scientists, Chris Carlson and David Weinberg, have founded a new company called ParcelBio.
The startup aims to address a technical limitation that has hindered the durability of mRNA-based medicines, which the founders say could unlock broader therapeutic potential.
ParcelBio has secured $13 million in seed financing to begin developing its platform and early drug candidates.
The funding will support preclinical work and further validation of the technology, positioning the company as a potential player in the evolving mRNA space.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Former Orbital scientists launch new mRNA therapy startup”
read at Endpoints ↗94 words · retrieved May 6
comments(0)
5-min edit window · permanent after that